Thrombotic Thrombocytopenic Purpura: Current Pathophysiology and Treatment
Keywords:
-Abstract
-
Downloads
References
Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med. 1925,36:89-93.
Symmers WSC. Thrombotic microangiopathic hemolytic anemia (thrombotic microangiopathy) BMJ 1952:2:897.
Gautier E, Siebenmann RE. The Birth of the Hemolytic-uremic syndrome. In: BS Kaplan, RS Trompeter, JL Moake, eds. Hemolytic uremic syndrome and Thrombotic thrombocytopenic purpura. Marcel Dekker: New York. 1992:19-27.
Amorosi EL, UItmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966;45:139-59.
Eldor A: Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy. Baillieres Clinical Haematology 1998;11:475-95.
Karmali MA, Steele BT, Petric M, et al. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin producing Escherichia col in stools. Lancet 1983;1:619.
McCrae KR, Cines D. Thrombotic thrombocytopenia and Hemolytic uremic syndrome. In: R Hoffman, EJ Benz, SJ Shattil, et al, eds. Hematology. Basic Principles and Practice, 3rd ed. Philadelphia: Churchill Livingstone. 2000:2126.
Ruggennenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura: Perspectives in basic science. Kidney Int 2001;60:831-46.
Dundas S, Murphy J, Soutar RL, et al. Effectiveness of therapeutic plasma exchange in the 1996. Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999,354:1327.
Assanasen J, Auewarakul C. Human Immunodeficiency Virus Infection and Thrombotic Thrombocytopenic Purpura: A Case Report and Review of the Literature. Intern Med J Thai. 2003 (in press).
Moake JL, Byrnes J. Thrombotic microangiopathies associated with drugs and marrow transplantation. Hematol Oncol Clin North Am 1996;10:485-95.
Tsai H-M, Rice L, Sarode R, Chow T, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;
:794-9.
Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000,342:1773-6.
Gordon LI, Kwann HC. Thrombotic microangiopathy manifestating as thrombotic thrombocytopenic purpura hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost. 1999;25:217-21.
Hogewind BL, Brutel de La Riviere G, van ES LA, et al. Familial occurrence of the haemolytic uraemic syndrome. Acta Med Scand 1980;207:73-6.
Barbot J, Costa E, Guerra M, et al. Ten years of prophylactic treatment with fresh frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol 2001;113:649-51.
Tarr PI, Neill MA, Allen J, et al. The increasing incidence of the hemolytic-uremic syndrome in King County, Washington: lack of evidence for ascertainment bias. Am J Epidemiol 1989;129:582.
Dang CT, Magid MS, Weksler B, et al. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood 1999,93:1264-70.
Laurence J, Mitra D, Steiner M, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus associated thrombotic thrombocytopenic purpura induced apoptosis in microvascular endothelial cells. Blood 1996;87:3245-54.
Jiminez JJ, Jy W, Mauro LM, et al. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol 2001;112:81-5.
Thomson C, Daman LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980's: Clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992;80:1890-5.
Murphy WG, Moore JC, Kelton JG. Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura. Blood 1987,70:1683-9.
Lian EC, Harkness DR, Byrnes JJ. Presence of a platelet-aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. Blood 1979;53:333-9.
Moore JC, Murphy WG, Kelton JG. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein ITb/IIla: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. Br J Haematol 1990;74:457-61.
Ying L, Katz Y, Schlesinger M, et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 1999;65:1538-41.
Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982,307:1432-5.
Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986,78.1456-61.
Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998;339:1578-84.
Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998,339:1585-94.
Fujikawa K, Suzuki H, McMullen B, Chung D. Purifcation of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001,98:1662-6.
Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von-Willebrand-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001;276:41059-63.
Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMT'S gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-9.
Zheng X, Majerus EM, Sadler JE. ADAMTS13 and TTP. Curr Opin Hematol. 2002;9:389-94.
Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombicytopenic purpura. Thromb Haemost 1999,81:8-13.
Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001;98:2728-33.
Kinoshita S, Yoshioka A, Park YD, et al. Upshaw- Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 2001;74:101-8.
Reiter RA, Knobl P, Varadi K, Turecek PL. Changes in von Willebrand-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003;101:946-8.
Asada Y, Sumiyoshi A, Hayashi I, et al. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985,38:469-72.
Kwann HC. Clinicopathologic features of thrombotic thrombocytopenic purpura. Semin Hematol 1987;24:71-81.
Gruber O, Wittig I, Wiggins CJ, et al. Thrombotic thrombocytopenic purpura: MRI demonstration of persistent small cerebral infarcts after clinical recovery. Neuroradiology 2000;42:616-9.
Crowley JP, Metzger JB, L'Europa RA. The blood counts and lactic dehydrogenase levels in thrombotic thrombocytopenic purpura. Am J Clin Pathol 1983;80:700-2.
Cohen JD, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apheresis 1998;13:16-9.
McMinn JR, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apheresis 2001;16:202-9.
George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000:96:1223-9.
Lee GR, Foerster J, Lukens J, eds. Wintrobe's Clinical Haematology, 10th edition. Williams and Wilkins: Maryland. 1999:1612.
Rubinstein MA, Kagan BM, MacGillviray MH, et al. Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions. Ann Intern Med 1959;51:1409.
Bukowski RM, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977;50:413-6.
Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenia purpura. N Engl J Med 1991,325:393-7.
Bandarenko N, Brecher ME, Members of the US TTP ASG. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group: Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apheresis. 1998;13:133-41.
Rock G, Shumak KH, Sutton DMC, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.Br J Haematol 1996,94:383-6.
Rizvi MA, Vesely SK, George JN, et al. Plasma exchange complications in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2000;40:896-901.
Gordon LI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol 1987;24:184.
de la Rubia J, Lopez A, Arriaga F, Cid AR, Vicente AI, Marty ML, et al. Response to plasma exchange and steroids as combined therapy for patients withthrombotic thrombocytopenic purpura. Acta Haematol 1999;102:12-6.
Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med 1991,325:398-403.
Pereira A, Mazzara R, Monteagudo J, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 1995;70:319-23.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
